10-K: INmune Bio Reports Full Year 2024 Results, CORDStrom Advances Towards BLA Filing

INmune Bio's 2024 annual report highlights progress in clinical trials, particularly for CORDStrom in RDEB, while acknowledging ongoing financial challenges and efforts to secure additional funding.

Summary

• INmune Bio Inc. reported its annual results for the fiscal year ended December 31, 2024.
• The company is focused on developing immunotherapies for diseases linked to innate immune system dysfunction, including cancer, Alzheimer's disease (AD), treatment-resistant depression (TRD), and recessive dystrophic epidermolysis bullosa (RDEB).
• A pivotal trial for CORDStrom in RDEB has been completed, with plans to submit a Biologics License Application (BLA) to the FDA in late 2025 or early 2026.
• A Phase II trial for XPro1595 in early AD has completed enrollment, with topline data expected in June 2025.
• The company is preparing for a Phase II trial of XPro1595 in TRD, supported by a $2.0 million grant from the National Institute of Mental Health (NIMH).
• An open-label Phase I/II trial of INKmune in metastatic castrate-resistant prostate cancer (mCRPC) is underway, with the final patient expected to be enrolled in the first half of 2025.
• The company reported a net loss of $42.1 million for 2024, compared to $30.0 million in 2023.
• As of December 31, 2024, cash and cash equivalents totaled $20.9 million.
• The company acknowledges substantial doubt about its ability to continue as a going concern and is actively pursuing additional funding.
• Research and development expenses increased to $33.2 million in 2024 from $20.3 million in 2023, driven by clinical trial costs.
• The company is leveraging proprietary techniques to manufacture human umbilical cord mesenchymal stromal cells (HucMSCs) for CORDStrom, aiming for batch-to-batch consistency and scalable production.
• The company has licensed clinical trial data from Great Ormond Street Hospital (GOSH) for CORDStrom, with milestone payments tied to regulatory approvals.
• The company is pursuing regulatory opportunities for expedited approval pathways, including Orphan Drug Designation and accelerated approval programs.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and regulatory designations, the financial losses and going concern uncertainty temper the overall outlook.

Positives

• CORDStrom has completed a pivotal trial for RDEB and is moving towards BLA submission.
• XPro1595 has completed Phase II enrollment for early AD, with topline data expected soon.
• The company has received RPDD and ODD for CORDStrom, which could lead to a Priority Review Voucher and other benefits.
• The company has a $2.0 million grant from the NIMH to support a Phase II TRD program.
• The company is leveraging proprietary techniques to manufacture human umbilical cord mesenchymal stromal cells (HucMSCs) for CORDStrom, aiming for batch-to-batch consistency and scalable production.

Negatives

• The company reported a net loss of $42.1 million for the year ended December 31, 2024.
• The company had cash and cash equivalents of $20.9 million as of December 31, 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain, requiring additional capital to finance operations.
• The biotechnology and immunotherapy industries are highly competitive, with larger companies possessing greater resources.
• Clinical drug development is a lengthy and expensive process with a high rate of failure.
• The company is dependent on the success of its DN-TNF product platform, Natural Killer Cell Priming Platform (INKmune), and CORDStrom.
• The company needs to attract and retain highly skilled personnel and may be unable to effectively manage growth with limited resources.
• The company relies on patents to protect its technology and may be unable to protect its intellectual property rights.

Future Outlook

The company plans to submit a BLA for CORDStrom in late 2025 or early 2026, file MAAs in the EU and UK in 2026, and present topline data from the Phase II AD trial in June 2025. They also plan to start a Phase II trial in TRD during 2025.

Industry Context

The report acknowledges the competitive landscape of the oncology and immunotherapy markets, highlighting the need to educate partners on the value of NK cell-based therapeutic strategies and the role of MUC4 in causing resistance to immunotherapy.

Comparison to Industry Standards

• The report mentions competitors in the NK cell therapy business, such as Century Therapeutics, Immunity Bio, Nkarta, Fate Therapeutics, and Glycostem.
• It also discusses companies in the personalized immuno-oncology business, including Bluebird, Juno Therapeutics, Mustang Bio, Novartis, and Gilead.
• The report notes the presence of large companies like Genentech/Roche, Amgen, and Merck in the antibody therapy space, and Merck and GSK in the checkpoint inhibitor field.
• Denali Therapeutics (NASDAQ: DNLI), Alector (NASDAQ: ALEC), Gliacure, and Eisai are mentioned as competitors in the Alzheimer's disease treatment space.

Legal Proceedings

• The Company has an ongoing dispute with a vendor in which the Company believes that the vendor did not properly provide services for which they have invoiced the Company.

Related Party Transactions

• The Company recorded prepaid expenses related party for payments made to UCL, where the Companys Chief Scientific and Manufacturing Officer is a professor.
• The Company paid AmplifyBio, where the CEO is on the Board of Directors of the Company, for research and development services.
• The Company licenses its INKmune patent from Immune Ventures, LLC, which is owned by the Company's CEO, CFO, and CSO.

Stakeholder Impact

• Shareholders face potential dilution from future stock offerings.
• Employees may be affected by the company's financial challenges and potential need to scale back operations.
• Patients with RDEB, AD, TRD, and cancer could benefit from the company's drug development efforts, but clinical trial outcomes and regulatory approvals are uncertain.
• Suppliers and creditors face potential risks related to the company's ability to meet its financial obligations.

Next Steps

• Submit a BLA to the FDA for CORDStrom in late 2025 or early 2026.
• File MAAs in the EU and United Kingdom for CORDStrom in 2026.
• Present topline data from the Phase II AD trial in June 2025.
• Start a Phase II trial in TRD during 2025.
• Complete enrollment in the Phase I/II trial of INKmune in mCRPC in 1H25.

Key Dates

Keywords

CORDStrom, INKmune, XPro1595, RDEB, Alzheimer's Disease, TRD, Immunotherapy, Clinical Trials, Financial Results, INmune Bio